View ValuationUrteste 将来の成長Future 基準チェック /06現在、 Urtesteの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長22.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • Dec 05New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł5.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł5.5m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 8.0% per year over the past 5 years. Revenue is less than US$1m (zł1.8m revenue, or US$496k). Minor Risk Market cap is less than US$100m (zł49.3m market cap, or US$13.6m).お知らせ • Aug 25Urteste S.A. to Report First Half, 2025 Results on Sep 29, 2025Urteste S.A. announced that they will report first half, 2025 results on Sep 29, 2025お知らせ • Jul 21Urteste S.A. Completes the Development Phase of Panuri Test and Reached Technological Readiness for Clinical Performance StudyUrteste S.A. has completed the development phase of its Panuri test and reached technological readiness for clinical performance study. The test is designed to detect pancreatic cancer - one of the most difficult cancers to diagnose. Clinical study in Europe are scheduled to begin in the third quarter of 2025. Urteste has developed all components of the Panuri test, including buffers, reagents, and a positive control. In-process control was conducted, and the pre-analytical phase was optimized, resulting in high-quality reagents with confirmed structure and purity, as well as reproducible test performance. The result-reading process has also been automated. As a result, the Panuri test complies with the IVDR - Regulation (EU) 2017/746 of the European Parliament and of the Council on in vitro diagnostic medical devices.New Risk • Jun 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł15m free cash flow). Earnings have declined by 8.0% per year over the past 5 years. Revenue is less than US$1m (zł1.5m revenue, or US$410k). Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (zł80.6m market cap, or US$21.5m).お知らせ • May 29Urteste S.A., Annual General Meeting, Jun 25, 2025Urteste S.A., Annual General Meeting, Jun 25, 2025.分析記事 • May 27Here's Why We're Watching Urteste's (WSE:URT) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...分析記事 • Dec 07Is Urteste (WSE:URT) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...分析記事 • Jul 19Urteste (WSE:URT) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...お知らせ • May 29Urteste S.A. Successfully Develops A Prototype Urine-Based Diagnostic Test for Detecting Brain TumoursUrteste S.A. developed a prototype IVD test for detecting brain tumours. Urteste now has a pipeline of 12 prototype diagnostic tests for the following cancers: pancreatic, brain, breast, stomach, bile ducts, ovary, endometrial, kidney, colorectal, lung, liver and prostate accounting collectively for nearly 70% of all cancer deaths worldwide. In the coming months, Urteste plans to start a multi- centre clinical trial in the US and Europe for its project PANURI, a test for pancreatic cancer. Urteste’s breakthrough technology allows for early detection of cancer by measuring the activity of enzymes present in urine using proprietary synthetic peptides. One urine sample can be used to screen for many types of cancers. Urteste technology is non-invasive, low-cost to produce, has high sensitivity and specificity, and results are available in up to 2 hours. The diagnostic process is automated to minimize the likelihood of human error. PANURI - the pancreatic cancer test is Urteste's most advanced project. Pancreatic cancer is one of the worst prognosis cancers. A proof-of-concept study of 322 participants confirmed the high sensitivity (95.6%) and specificity (95.5%) of the PANURI test. Urteste is currently undergoing an FDA Q-Submission programme. In the MULTI-CANCER project, Urteste is developing a diverse portfolio of tests. The company already has prototypes of 12 diagnostic tests for the most common cancers. In the coming months, Urteste plans to add the final prototypes to its pipeline and complete the prototype development phase of the tests. The company will then focus on preparing for clinical trials. Urteste holds polish patents and international patent applications for its technology. Urteste's patent strategy is to seek patent protection in countries that collectively generate around 90% of global GDP.お知らせ • May 21Urteste S.A., Annual General Meeting, Jun 14, 2024Urteste S.A., Annual General Meeting, Jun 14, 2024.お知らせ • Jan 19+ 3 more updatesUrteste S.A. to Report Q3, 2024 Results on Nov 28, 2024Urteste S.A. announced that they will report Q3, 2024 results on Nov 28, 2024New Risk • Jun 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 24% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (zł155.1m market cap, or US$38.0m).お知らせ • May 31Urteste S.A., Annual General Meeting, Jun 22, 2023Urteste S.A., Annual General Meeting, Jun 22, 2023, at 14:00 Central European Standard Time.お知らせ • May 28+ 1 more updateUrteste S.A. to Report First Half, 2023 Results on Sep 29, 2023Urteste S.A. announced that they will report first half, 2023 results on Sep 29, 2023お知らせ • Jan 26+ 3 more updatesUrteste S.A. to Report Q3, 2023 Results on Nov 13, 2023Urteste S.A. announced that they will report Q3, 2023 results on Nov 13, 2023 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Urteste は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測WSE:URT - アナリストの将来予測と過去の財務データ ( )PLN Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/20252-5-56N/A6/30/20252-4-15-3N/A3/31/20252-3-15-4N/A12/31/20242-4-14-5N/A9/30/20241-3-12-5N/A6/30/20241-4-11-6N/A3/31/20242-5-8-6N/A12/31/20231-6-7-5N/A9/30/20230-6-6-4N/A6/30/20230-5-4-4N/A3/31/20230-4-5-4N/A12/31/20220-4-5-4N/A12/31/2021N/A-4-3-2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: URTの予測収益成長が 貯蓄率 ( 5.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: URTの収益がPolish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: URTの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: URTの収益がPolish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: URTの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: URTの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 04:10終値2026/05/21 00:00収益2025/09/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Urteste S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Sylwia JaskiewiczDom Maklerski Banku Ochrony Srodowiska S.A.
New Risk • Dec 05New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł5.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł5.5m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 8.0% per year over the past 5 years. Revenue is less than US$1m (zł1.8m revenue, or US$496k). Minor Risk Market cap is less than US$100m (zł49.3m market cap, or US$13.6m).
お知らせ • Aug 25Urteste S.A. to Report First Half, 2025 Results on Sep 29, 2025Urteste S.A. announced that they will report first half, 2025 results on Sep 29, 2025
お知らせ • Jul 21Urteste S.A. Completes the Development Phase of Panuri Test and Reached Technological Readiness for Clinical Performance StudyUrteste S.A. has completed the development phase of its Panuri test and reached technological readiness for clinical performance study. The test is designed to detect pancreatic cancer - one of the most difficult cancers to diagnose. Clinical study in Europe are scheduled to begin in the third quarter of 2025. Urteste has developed all components of the Panuri test, including buffers, reagents, and a positive control. In-process control was conducted, and the pre-analytical phase was optimized, resulting in high-quality reagents with confirmed structure and purity, as well as reproducible test performance. The result-reading process has also been automated. As a result, the Panuri test complies with the IVDR - Regulation (EU) 2017/746 of the European Parliament and of the Council on in vitro diagnostic medical devices.
New Risk • Jun 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł15m free cash flow). Earnings have declined by 8.0% per year over the past 5 years. Revenue is less than US$1m (zł1.5m revenue, or US$410k). Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (zł80.6m market cap, or US$21.5m).
お知らせ • May 29Urteste S.A., Annual General Meeting, Jun 25, 2025Urteste S.A., Annual General Meeting, Jun 25, 2025.
分析記事 • May 27Here's Why We're Watching Urteste's (WSE:URT) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
分析記事 • Dec 07Is Urteste (WSE:URT) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
分析記事 • Jul 19Urteste (WSE:URT) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
お知らせ • May 29Urteste S.A. Successfully Develops A Prototype Urine-Based Diagnostic Test for Detecting Brain TumoursUrteste S.A. developed a prototype IVD test for detecting brain tumours. Urteste now has a pipeline of 12 prototype diagnostic tests for the following cancers: pancreatic, brain, breast, stomach, bile ducts, ovary, endometrial, kidney, colorectal, lung, liver and prostate accounting collectively for nearly 70% of all cancer deaths worldwide. In the coming months, Urteste plans to start a multi- centre clinical trial in the US and Europe for its project PANURI, a test for pancreatic cancer. Urteste’s breakthrough technology allows for early detection of cancer by measuring the activity of enzymes present in urine using proprietary synthetic peptides. One urine sample can be used to screen for many types of cancers. Urteste technology is non-invasive, low-cost to produce, has high sensitivity and specificity, and results are available in up to 2 hours. The diagnostic process is automated to minimize the likelihood of human error. PANURI - the pancreatic cancer test is Urteste's most advanced project. Pancreatic cancer is one of the worst prognosis cancers. A proof-of-concept study of 322 participants confirmed the high sensitivity (95.6%) and specificity (95.5%) of the PANURI test. Urteste is currently undergoing an FDA Q-Submission programme. In the MULTI-CANCER project, Urteste is developing a diverse portfolio of tests. The company already has prototypes of 12 diagnostic tests for the most common cancers. In the coming months, Urteste plans to add the final prototypes to its pipeline and complete the prototype development phase of the tests. The company will then focus on preparing for clinical trials. Urteste holds polish patents and international patent applications for its technology. Urteste's patent strategy is to seek patent protection in countries that collectively generate around 90% of global GDP.
お知らせ • May 21Urteste S.A., Annual General Meeting, Jun 14, 2024Urteste S.A., Annual General Meeting, Jun 14, 2024.
お知らせ • Jan 19+ 3 more updatesUrteste S.A. to Report Q3, 2024 Results on Nov 28, 2024Urteste S.A. announced that they will report Q3, 2024 results on Nov 28, 2024
New Risk • Jun 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 24% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (zł155.1m market cap, or US$38.0m).
お知らせ • May 31Urteste S.A., Annual General Meeting, Jun 22, 2023Urteste S.A., Annual General Meeting, Jun 22, 2023, at 14:00 Central European Standard Time.
お知らせ • May 28+ 1 more updateUrteste S.A. to Report First Half, 2023 Results on Sep 29, 2023Urteste S.A. announced that they will report first half, 2023 results on Sep 29, 2023
お知らせ • Jan 26+ 3 more updatesUrteste S.A. to Report Q3, 2023 Results on Nov 13, 2023Urteste S.A. announced that they will report Q3, 2023 results on Nov 13, 2023